June 21, 2016, 9am – 1pm Wasserstein Hall, Milstein East (2036), Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA This event is free and open to the public, but seating is limited. Register now! Description Please join us for the inaugural event of the Project on Advanced Care and Health Policy, a collaboration between the…
June 21, 2016, 9am – 1pm Wasserstein Hall, Milstein East (2036), Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA This event is free and open to the public, but seating is limited. Register now! Description Please join us for the inaugural event of the Project on Advanced Care and Health Policy, a collaboration between the…
By Norman L. Cantor I am obsessed with avoiding severe dementia. As a person who has always valued intellectual function, the prospect of lingering in a dysfunctional cognitive state is distasteful — an intolerable indignity. For me, such mental debilitation soils the remembrances to be left with my survivors and undermines the life narrative as…
By Arthur Caplan A new piece by contributor Art Caplan on NBC News: Biogen, a Cambridge, Massachusetts biotech company, announced last week that early tests of their new drug aducanumab, a monoclonal antibody, had shown impressive results in treating those with early stage Alzheimer’s disease. The drug significantly reduced the amyloid plaque buildup in the…
By The Petrie-Flom Center Call for Papers, AALS Joint Program Section on Aging and the Law ● Section on Law, Medicine, and Health Care 2015 AALS Annual Meeting in Washington, D.C. January 3, 2015 from 3:30 to 5:15 p.m. Unbefriended Elderly: Making Medical Treatment Decisions for Patients without Surrogates The AALS Section on Aging and…
By Matthew L Baum This past Sunday, a group of researchers reported in the journal, Nature Medicine, a preliminary technique that uses variation in blood levels of 10 fats to predict the likelihood that elderly individuals would develop mild cognitive impairment (MCI) or Alzheimer’s Disease in the following 2-3 years. The sample size was small…
By Jonathan J. Darrow In January, the Food and Drug Administration (FDA) approved the use of the PillCam COLON 2 as a minimally-invasive means of viewing the colon, a development that is sure to be welcomed by U.S. patients who currently undergo an estimated 14 million colonoscopies each year. While the approval represents a major step…
By Matthew Lawrence Yesterday the HHS Office of Medicare Hearings and Appeals (OMHA) held a forum for appellants affected by its decision, which I blogged about last month, to hold off on assigning incoming appeals to ALJs while they work to clear a large backlog. I was able to go, and enjoyed every minute. This…
By I. Glenn Cohen [This is off-the-cuff live blogging, so apologies for any errors, typos, etc] Panel 1: FDA in a Changing World: Lewis Grossman, Ted Ruger, Barbara Evans, moderated by Holly Fernandez Lynch Lewis Grossman, FDA in the Age of the Empowered Consumer Begins his analysis by comparing a hypothetical consumer in 1960 and…
By Casey Thomson This week’s slightly belated round-up concerns palliative care across cultures, the threat and problems of over-prescribing, and Big Pharma’s failure to create prices with the patient in mind. Read on for more from this week’s round-up. Alex Smith (@AlexSmithMD) retweeted a piece on the lessons learned by Dr. Vvjeyanthi “V.J.” Periyakoil on…
